Strong cytoplasmic expression of COX2 at the invasive fronts of gallbladder cancer is associated with a poor prognosis

Journal of Clinical Pathology

Volumn 63, Issue 12, 2010, Pages 1048-1053

  Kim, Haeryoung ^a   Song, Joo Yeon ^a,b   Cho, Jai Young ^a   Yoon, Yoo Seok ^a   Han, Ho Seong ^a   Lee, Hye Seung ^a   Ryu, Han Suk ^a   Choe, Gheeyoung ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Department of Pathology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; CYTOPLASM; EPIDEMIOLOGIC METHODS; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649629035     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.080713     Document Type: Article

References (36)

1. Rückert JC, Rückert RI, Gellert K, et al. Surgery for carcinoma of the gallbladder. Hepatogastroenterology 1996;43:527-33.
2. Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 2000;232:557-69.
3. Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg 1994;219:275-80.
4. Albores-Saavedra J, Scoazec JC, Wittekind C, et al. Carcinoma of the gallbladder and extrahepatic bile ducts. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumors of the Digestive System. Lyon: IARC Press 2000:206-14.
5. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. TRENDS Pharmacol Sci 2003;24:96-102. (Pubitemid 36135884)
6. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94. (Pubitemid 30390309)
7. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increase metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40. (Pubitemid 27157312)
8. Zhi YH, Liu RS, Song MM, et al. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 2005;11:3724-8.
9. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66. (Pubitemid 34196319)
10. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5. (Pubitemid 34126931)
11. Eschwege P, Ferlicot S, Droupy S, et al. A histopathologic investigation of PGE2 pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur Urol 2003;44:435-41.
12. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia. An immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002;118:194-201.
13. Panagopoulos AT, Lancellotti CL, Veiga JC, et al. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol 2008;89:73-87.
14. Hayashi N, Yamamoto H, Hiraoka N, et al. Differential expression of cyclooxygenase-2 (COX2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 2001;34:638-50.
15. Le NH, Franken P, Fodde R. Tumor-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness. Br J Cancer 2008;98:1886-93.
16. Del Casar JM, González LO, Alvarez E, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009;116:39-52.
17. Horree N, van Diest PJ, Sie-Go DM, et al. The invasive front in endometrial carcinoma: higher proliferation and associated derailment of cell cycle regulators. Hum Pathol 2007;38:1232-8.
18. Kawamoto T, Shoda J, Asano T, et al. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 2002;98:427-34.
19. Asano T, Shoda J, Ueda T, et al. Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 2002;8:1157-67.
20. Legan M, Luzar B, Marolt VF, et al. Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol 2006;12:3425-9.
21. Karamitopoulou E, Tornillo L, Zlobec I, et al. Clinical significance of cell cycle-and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 2008;130:780-6.
22. Schmitz KJ, Lang H, Wohlschlaeger J, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch 2007;450:135-41.
23. Kim HJ, Lee KT, Kim EK, et al. Expression of cyclooxygenase-2 in cholangiocarcinoma: correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol 2004;19:582-8.
24. Hu M, Peluffo G, Chen H, et al. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 2009;106:3372-7.
25. de Maat MFG, van de Velde CJH, Umetani N, et al. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 2007;25:4887-94.
26. De Moraes E, Dar NA, de Moura Gallo CV, et al. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer 2007;121:929-37.
27. Takagawa M, Muguruma N, Oguri K, et al. Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry. Dig Dis Sci 2005; 50:1410-13.
28. da Rocha AO, Coutinho LM, Scholl JG, et al. The value of p53 protein expression in gallbladder carcinoma: analysis of 60 cases. Hepatogastroenterology 2004;51:1310-14.
29. Li X, Hui AM, Shi YZ, et al. Reduced p21WAF1/CIP1 expression is an early event of gallbladder carcinogenesis and is of prognostic significance for patients with carcinomas of the gallbladder. Hum Pathol 2001;32:771-7.
30. Chang HJ, Yoo BC, Kim SW, et al. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 2007;13:326-35.
31. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of Dpc4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts: evidence for a biologic distinction. Cancer 2001;91:1332-41.
32. Kim WB, Han HJ, Lee HJ, et al. Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer. Ann Surg Oncol 2009;16:23-34.
33. Roninson IB. Oncogenic functions of tumor suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumor-promoting activities of stromal fibroblasts. Cancer Lett 2002;179:1-14.
34. Puhalla H, Wrba F, Kandioler D, et al. Expression of p21(Waf1/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer. Anticancer Res 2007;27:1679-84.
35. Li X, Hui A, Takayama T, et al. Altered p21(WAF1/CIP1) expression is associated with poor prognosis in extrahepatic bile duct carcinoma. Cancer Lett 2000;154:85-91.
36. Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006;24:1152-60.